Schizophrenia Clinical Trials

83 studies are recruiting for schizophrenia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

   Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Hotei Hospital, Konan-shi, Aichi-ken

   Locations

   73 in total

   Run by

   Otsuka Pharmaceutical Development & Commercialization, Inc.

   See if you can join NCT06894212 on ClinicalTrials.gov

2. Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

   The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Pillar Clinical Research LLC, Bentonville, Arkansas

   Locations

   16 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT07467993 on ClinicalTrials.gov

3. Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

   This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Pillar Clinical Research, Bentonville, Arkansas

   Locations

   13 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07363577 on ClinicalTrials.gov

4. Tolerability of MDMA in Schizophrenia

   Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness. Whereas many symptoms of schizophrenia can be treated with antipsychotic medications, deficits in social motivation persist, leading to signific…

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   UCLA, Los Angeles, California

   Run by

   Anya Bershad, MD, PhD

   See if you can join NCT05770375 on ClinicalTrials.gov

5. Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental Illness

   The proposed research will test the hypothesis that objective social isolation and loneliness are linked to neurobehavioral mechanisms involved in social perception and motivation in individuals with and without serious mental illness. Moreover, it will investigate the specific dynamic interactions…

   Stage

   Not phased

   Ages

   18 to 55

   Site

   Massachusetts General Hospital, Charlestown, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT04940663 on ClinicalTrials.gov

6. Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

   Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Acacia Clinics, Sunnyvale, California

   Locations

   2 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT06376734 on ClinicalTrials.gov

7. Anticholinergic Deprescription in Schizophrenia

   In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unnee…

   Stage

   Phase 4

   Ages

   40 to 70

   Site

   UPMC Western Psychiatric Hospital/University of Pittsburgh, Pittsburgh, Pennsylvania

   Run by

   Deepak K. Sarpal, M.D.

   See if you can join NCT06562608 on ClinicalTrials.gov

8. Acetazolamide for Treatment Resistant Schizophrenia

   This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   University of Pittsburgh, Pittsburgh, Pennsylvania

   Locations

   2 in total

   Run by

   Vishwajit Nimgaonkar, MD PhD

   See if you can join NCT04887792 on ClinicalTrials.gov

9. Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)

   Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.

   Stage

   Not phased

   Ages

   18 to 60

   Site

   The University of Texas Health Science Center, Houston, Houston, Texas

   Run by

   The University of Texas Health Science Center, Houston

   See if you can join NCT06345963 on ClinicalTrials.gov

10. Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)

    Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil combined with cognitive training for improving white matter integrity.

    Stage

    Not phased

    Ages

    18 to 60

    Site

    The University of Texas Health Science Center, Houston, Houston, Texas

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT06961916 on ClinicalTrials.gov

11. Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness

    This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI). The two-arm randomized controlled trial will compare the efficacy of YE compared to the Wellness Lifestyle Program (WLP). Prima…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania

    Run by

    VA Office of Research and Development

    See if you can join NCT05157620 on ClinicalTrials.gov

12. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Bryant, Arkansas

    Locations

    57 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

13. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Garden Grove, California

    Locations

    20 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov

14. Restoring Spindle and Thalamocortical Efficiency in Early-Course Schizophrenia Patients Using Auditory Stimulation

    The purpose of this research is to identify differences in brain activity during sleep between health individuals and individuals with schizophrenia, schizophreniform, or schizoaffective disorder. This study will also investigate whether tones played during deep sleep can enhance specific features …

    Stage

    Not phased

    Ages

    18 to 40

    Site

    University of Pittsburgh, Pittsburgh, Pennsylvania

    Run by

    Fabio Ferrarelli

    See if you can join NCT05956951 on ClinicalTrials.gov

15. Anti-Inflammatory Challenge in Schizophrenia

    This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain circuits. The primary goal of this study is to determine: * Ventral St…

    Stage

    Phase 4

    Ages

    18 to 55

    Site

    Grady Memorial Hospital, Atlanta, Georgia

    Locations

    2 in total

    Run by

    Emory University

    See if you can join NCT05823532 on ClinicalTrials.gov

16. A Study to Evaluate the Effect of KarXT on Urological Safety

    The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Pillar Clinical Research- Little Rock, Little Rock, Arkansas

    Locations

    13 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07221877 on ClinicalTrials.gov

17. Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia

    The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitan…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Vanderbilt Psychiatric Hospital, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT07196462 on ClinicalTrials.gov

18. Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

    The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated levels of sugar and bad cholesterol. Participants will be randomly assigned to either take lumateperone …

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    UMass Chan Medical School, Worcester, Massachusetts

    Run by

    University of Massachusetts, Worcester

    See if you can join NCT06174116 on ClinicalTrials.gov

19. NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Culver City, California

    Locations

    15 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07105098 on ClinicalTrials.gov

20. CLOZAPINE Response in Biotype-1

    The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as ps…

    Stage

    Phase 4

    Ages

    18 to 60

    Site

    Hartford Healthcare, Hartford, Connecticut

    Locations

    5 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04580134 on ClinicalTrials.gov

21. Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

    Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the …

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    University of California, Los Angeles, Los Angeles, California

    Locations

    7 in total

    Run by

    New York State Psychiatric Institute

    See if you can join NCT05208190 on ClinicalTrials.gov

22. Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

    Low social motivation is a significant symptom of schizophrenia and is a major cause of disability and suffering for many patients struggling with the illness. Social motivation refers to the drive to participate in or abstain from social activities. Many patients with schizophrenia evidence both d…

    Stage

    Phase 2

    Ages

    18 to 60

    Site

    UCLA Semel Institute, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT05778591 on ClinicalTrials.gov

23. Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

    The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (P…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT01730781 on ClinicalTrials.gov

24. Database Registry for Neural Network Biomarkers in Psychosis

    Several observations have been made with magnetic resonance imaging (MRI) that characterize brain connections and brain function in individuals with schizophrenia and other mental disorders. For example, research investigating schizophrenia focuses on the dysfunction of connections within and betwe…

    Stage

    Not phased

    Ages

    18 to 60

    Site

    University of Texas Southwestern Medical Center, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT01409109 on ClinicalTrials.gov

25. Synbiotic Compound to Reduce Symptoms of Schizophrenia

    The purpose of this study is to determine if taking a synbiotic supplement versus a placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic medications.

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Sheppard Pratt Health System, Batlimore, Maryland

    Run by

    Sheppard Pratt Health System

    See if you can join NCT04226898 on ClinicalTrials.gov